Enasidenib
Drug timelines are a Plus or Pro feature.
15 regulatory and trial events tracked for Enasidenib, covering 2015-12-14 to 2026-04-24. Get the full timeline:
Most recent: Clinical Trial Update: Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial) [Phase 2]